Fil LTD Intellia Therapeutics, Inc. Transaction History

Fil LTD

$103 Billion
Q3 2024

A detailed history of Fil LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Fil LTD holds 19,063 shares of NTLA stock, worth $272,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,063

Previous 18,465 3.24%

Holding current value

$272,600

Previous $413,000 5.33%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$19.72 - $27.36 $11,792 - $16,361	598 Added 3.24%	19,063 $391,000
Q2 2024 Aug 13, 2024	BUY	$20.02 - $27.22 $176,996 - $240,652	8,841 Added 91.86%	18,465 $413,000
Q1 2024 May 13, 2024	BUY	$23.82 - $32.8 $16,221 - $22,336	681 Added 7.61%	9,624 $264,000
Q4 2023 Feb 13, 2024	BUY	$23.16 - $32.34 $207,119 - $289,216	8,943 New	8,943 $272,000
Q1 2023 May 11, 2023	SELL	$33.3 - $44.82 $3,829 - $5,154	-115 Reduced 0.14%	80,000 $2.98 Million
Q4 2022 Feb 13, 2023	BUY	$33.21 - $62.69 $2.66 Million - $5.02 Million	80,115 New	80,115 $2.8 Million

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.09B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.

Account